Dolby Laboratories, Inc. (DLB)’s Stock Insider Trading – Mark Sherman Sold 81,554 Shares; Agios Pharmaceuticals Has 1.21 Sentiment

After the publishing of a public report filled with Security and Exchange Commission; a substantial trade became apparent. The EVP – GEN. COUN. & SECRTY of Dolby Laboratories Inc, Mark Sherman; executed a huge trade in the open market by selling 81,554 shares at an avg market stock price per share of $62.5 of the ‘s company valued at near $5,098,724 U.S Dollars. In the last month, he also sold 10,000 shares with a total value $650,000 USD. This deal was pretty huge one, so clearly it won’t go undiscovered. At present, he owns a total of 47,566 shares or 0.05% of Dolby Laboratories Inc’s total market capitalization.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $4.07 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Since August 11, 2017, it had 0 insider purchases, and 17 selling transactions for $43.57 million activity. On Monday, January 22 the insider JASPER N WILLIAM JR sold $2.56 million. 9,310 shares were sold by GOTCHER PETER C, worth $558,600. SHERMAN MARK ANDREW sold $787,500 worth of stock or 14,000 shares. The insider Dolby Dagmar sold 100,000 shares worth $4.95 million. YEAMAN KEVIN J had sold 45,000 shares worth $2.54 million.

Investors sentiment decreased to 1.04 in Q3 2017. Its down 0.43, from 1.47 in 2017Q2. It dropped, as 28 investors sold Dolby Laboratories, Inc. shares while 71 reduced holdings. 33 funds opened positions while 70 raised stakes. 52.63 million shares or 2.95% more from 51.12 million shares in 2017Q2 were reported. Macquarie Group holds 600 shares or 0% of its portfolio. Price Michael F reported 6.76% in Dolby Laboratories, Inc. (NYSE:DLB). Da Davidson And Communications invested 0.03% of its portfolio in Dolby Laboratories, Inc. (NYSE:DLB). Advisory Limited Liability Company invested in 0% or 170 shares. Ohio-based Employees Retirement Systems Of Ohio has invested 0.03% in Dolby Laboratories, Inc. (NYSE:DLB). Brown Brothers Harriman & holds 0% in Dolby Laboratories, Inc. (NYSE:DLB) or 161 shares. 8,467 are owned by Peak6 Invests L P. Hightower Advsr Ltd Limited Liability Company stated it has 0% in Dolby Laboratories, Inc. (NYSE:DLB). Janney Montgomery Scott Ltd Liability Co accumulated 0.02% or 23,934 shares. Fuller And Thaler Asset holds 1.34M shares. 16,749 are held by Bb&T Limited Liability Company. Moreover, Aimz Inv Advsrs Limited Co has 1.57% invested in Dolby Laboratories, Inc. (NYSE:DLB). Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0% or 2,331 shares. Carroll Assocs Inc holds 0% or 105 shares. Sandy Spring Bancorporation owns 0.09% invested in Dolby Laboratories, Inc. (NYSE:DLB) for 16,583 shares.

Dolby Laboratories, Inc. creates audio and imaging technologies that transform entertainment and communications at the cinema, at home, at work, and on mobile devices. The company has market cap of $6.23 billion. The firm develops and licenses its audio technologies, including Dolby Digital Plus for digital television, mobile, and Internet services; Dolby Digital, a digital audio coding technology that provides multichannel sound in the home; and AAC & HE-AAC, an audio coding technologies used to broadcast, download, and streaming content. It has a 93.32 P/E ratio. The Company’s audio technologies also comprise Dolby TrueHD, an audio coding technology for content providers; Dolby Atmos, an object-oriented audio technology for home theaters, device speakers, and headphones; Dolby AC-4, a digital audio coding system that addresses the current and future needs of broadcast and streaming entertainment services; Dolby Voice, an audio conferencing technology; and Dolby Vision, an imaging technology for cinema, digital television, and other consumer devices, as well as HEVC, a digital video codec with higher bandwidth efficiency used in a range of media devices.

The stock increased 0.35% or $0.21 during the last trading session, reaching $60.19. About 579,102 shares traded or 58.86% up from the average. Dolby Laboratories, Inc. (NYSE:DLB) has risen 14.35% since February 10, 2017 and is uptrending. It has underperformed by 2.35% the S&P500.

Among 6 analysts covering Dolby Laboratories (NYSE:DLB), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Dolby Laboratories has $70 highest and $38 lowest target. $62.42’s average target is 3.70% above currents $60.19 stock price. Dolby Laboratories had 17 analyst reports since October 22, 2015 according to SRatingsIntel. B. Riley & Co maintained Dolby Laboratories, Inc. (NYSE:DLB) rating on Thursday, October 22. B. Riley & Co has “Neutral” rating and $41 target. The rating was maintained by B. Riley & Co with “Buy” on Friday, August 18. The rating was downgraded by FBR Capital to “Hold” on Thursday, January 25. The company was maintained on Thursday, October 19 by B. Riley & Co. Piper Jaffray maintained the stock with “Hold” rating in Monday, January 22 report. B. Riley & Co maintained Dolby Laboratories, Inc. (NYSE:DLB) rating on Thursday, October 26. B. Riley & Co has “Buy” rating and $65.5 target. The rating was maintained by Piper Jaffray with “Hold” on Friday, July 14. The firm has “Hold” rating given on Wednesday, July 26 by Piper Jaffray. Dougherty maintained Dolby Laboratories, Inc. (NYSE:DLB) on Wednesday, September 13 with “Buy” rating. JP Morgan maintained the stock with “Neutral” rating in Thursday, January 25 report.

Bb Biotech Ag holds 5.08% of its portfolio in Agios Pharmaceuticals, Inc. for 2.75 million shares. Opaleye Management Inc. owns 130,000 shares or 3.07% of their US portfolio. Moreover, Opus Point Partners Management Llc has 2% invested in the company for 33,347 shares. The Massachusetts-based Fernwood Investment Management Llc has invested 1.16% in the stock. Capital International Ltd Ca, a California-based fund reported 241,337 shares.

Analysts await Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report earnings on February, 15. They expect $-1.65 earnings per share, down 23.13% or $0.31 from last year’s $-1.34 per share. After $-1.59 actual earnings per share reported by Agios Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 3.77% negative EPS growth.

The stock decreased 1.55% or $1.15 during the last trading session, reaching $73.11. About 633,609 shares traded or 12.44% up from the average. Agios Pharmaceuticals, Inc. (AGIO) has risen 8.52% since February 10, 2017 and is uptrending. It has underperformed by 8.18% the S&P500.

Since January 1, 0001, it had 0 insider purchases, and 22 sales for $25.02 million activity.

Ratings analysis reveals 100% of Agios Pharma’s analysts are positive. Out of 2 Wall Street analysts rating Agios Pharma, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. AGIO was included in 2 notes of analysts from October 24, 2016. As per Monday, October 24, the company rating was initiated by Needham. The stock has “Outperform” rating by Oppenheimer on Tuesday, January 17.